Alcon Inc. - Registered Shares

Alcon, Inc. engages in the development, manufacture, and marketing of market surgical equipment and devices, pharmaceutical eye drops, and consumer vision care products to treat eye diseases and disorders. It operates through the following segments: Surgical and Vision Care. The Surgical segment offers implantable products, consumables and equipment for use in surgical procedures to address cataracts, vitreoretinal conditions, refractive errors, and glaucoma. The Vision Care segment comprises daily disposable, reusable and color-enhancing contact lenses, as well as portfolio of ocular health products, including over-the-counter products for dry eye, contact lens care, and ocular allergies, as well as ocular vitamins and redness relievers. The company was founded by Mr. Robert Alexander and Mr. William Conner on 1945 and is headquartered in Geneva, Switzerland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GENEVA--( BUSINESS WIRE )--Alcon Inc. ("Alcon") (SIX/NYSE: ALC) announced that it has commenced and priced a private offering of US$700 million aggregate principal amount of its 5.375% senior notes due 2032 and US$600 million aggregate principal amount of its 5.750% senior notes due 2052 (together, the “Notes”). The Notes will be issued by Alcon Finance Corporation, Alcon's indirect subsidiary, and will be fully and unconditionally guaranteed on a senior basis by Alcon.

Alcon Prices US$1.3 Billion Senior Notes Offering

Alcon's (ALC) ophthalmic pharmaceutical product suite is expected to be significantly boosted by adding new products following the recent acquisition.

Alcon's (ALC) Latest Buyout to Enhance Its Product Portfolio

Alcon's (ALC) robust innovation pipeline is delivering solid results as evidenced by the strength in its comprehensive portfolio of PCIOLs, including PanOptix and Vivity.

Alcon (ALC) Q3 Earnings Surpass Estimates, Sales Guidance Cut

Aerie Pharmaceuticals

GENEVA--( BUSINESS WIRE )--Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced that it has completed its acquisition of Aerie Pharmaceuticals, Inc. (NASDAQ: AERI, “Aerie”). This transaction helps bolster Alcon's presence in the ophthalmic pharmaceutical space with its growing portfolio of commercial products and development pipeline.

Alcon Completes Acquisition of Aerie Pharmaceuticals, Inc., Strengthening Company's Ophthalmic Pharmaceutical Business

It's rare to find a high-growth foreign company that isn't stuck in a big downtrend. While ALC shares are down sharply year-on-year, its valuation is not so bad considering impressive EPS growth.

Alcon: Eyeing A Growth Story That Could Benefit From A Weaker Dollar

Alcon Inc. (NYSE:ALC ) Q3 2022 Earnings Conference Call November 16, 2022 8:00 AM ET Company Participants Dan Cravens - Vice President and Global Head, Investor Relations David Endicott - Chief Executive Officer Tim Stonesifer - Chief Financial Officer Conference Call Participants Ryan Zimmerman - BTIG Julien Dormois - BNP Paribas Daniel Buchta - ZKB Larry Biegelsen - Wells Fargo Matthew Mishan - KeyBanc Capital Markets Jeff Johnson - Baird Cecilia Furlong - Morgan Stanley Joanne Wuensch - Citi Falko Friedrichs - Deutsche Bank Zach Weiner - Jeffries Operator Greetings. And welcome to the Alcon Third Quarter 2022 Earnings Call.

Alcon Inc. (ALC) Q3 2022 Earnings Call Transcript

Advance Auto Parts

Investors didn't expect what these companies had to say.

2 Surprising Movers in the Stock Market Today

GENEVA--( BUSINESS WIRE )--Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the three and nine months ended September 30, 2022. For the third quarter of 2022, sales were $2.1 billion, an increase of 2% on a reported basis and 9% on a constant currency basis(2), as compared to the same quarter of the previous year. Alcon reported diluted earnings per share of $0.23 and core diluted earnings per share of $0.50.

Alcon Reports Third Quarter 2022 Results

FORT WORTH, Texas--(BUSINESS WIRE)--Alcon to Celebrate 75 Years of Brilliance and Showcase Contact Lens Innovations at #Academy22

Alcon to Celebrate 75 Years of Brilliance and Showcase Contact Lens Innovations at #Academy22

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C.

AERIE PHARMACEUTICALS - INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Aerie Pharmaceuticals, Inc. - AERI

With the latest launch of Clareon Toric, Alcon's (ALC) Clareon Collection of IOLs is complete in the United States.

Alcon (ALC) Clareon Suite to Get a Boost With Product Launch

FORT WORTH, Texas--(BUSINESS WIRE)--Alcon Completes Availability of Clareon Portfolio with Clareon Toric During AAO 2022

Alcon Completes Availability of Clareon Portfolio with Clareon Toric During AAO 2022

NEW ORLEANS , Sept. 27, 2022 /PRNewswire/ -- Former Attorney General of Louisiana Charles C.

AERIE PHARMACEUTICALS - INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Aerie Pharmaceuticals, Inc. - AERI

Given the supply chain challenges, unfavorable foreign exchange impact and inflationary pressure, Alcon (ALC) reduces its core EPS and net sales expectations for 2022.

Alcon (ALC) Faces Cost Pressure, Supply Chain Disruption

Alcon has continued in a downtrend since September 2021 with persistent mean reversion activity across this time. With FY22 guidance narrowed and macro-headwinds prevailing, forward-looking multiples are less attractive to peers.

Alcon: Looking To Break Downtrend Before Entry

Novartis

Most investors would probably be pleased with a share price gain of 33% in just over three years, but more than 50% sounds a lot better.

Don't Look for Alcon's Acquisition to Boost Share Price in Short Term

NEW YORK , Aug. 23, 2022 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Aerie Pharmaceuticals, Inc. ("Aerie" or the "Company") (NASDAQ: AERI), in connection with the proposed acquisition of the Company by Alcon Inc. (NYSE: ALC).  Under the terms of the merger agreement, the Company's shareholders will receive $15.25 in cash for each share of Aerie common stock owned.

SHAREHOLDER ALERT: Weiss Law Investigates Aerie Pharmaceuticals, Inc.

Alcon will buy glaucoma drugs maker Aerie Pharmaceuticals in a $770 million deal that sent the biotech stock flying Tuesday. The post Blistering-Hot Biotech Shopping Spree Continues: Alcon To Buy Aerie For $770 Million appeared first on Investor's Business Daily.

Blistering-Hot Biotech Shopping Spree Continues: Alcon To Buy Aerie For $770 Million

Alcon agrees to acquire Aerie, the ophthalmic therapies company, for $15.25 a share.

Alcon to Acquire Aerie Pharmaceuticals for $15.25 a Share

GENEVA & DURHAM, N.C.--(BUSINESS WIRE)--Regulatory News: Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, and Aerie Pharmaceuticals, Inc. (NASDAQ: AERI, “Aerie”), a pharmaceutical company focused on the discovery, development, manufacturing and commercialization of first-in-class ophthalmic therapies, today announced the companies have entered into a definitive merger agreement through which Alcon will acquire Aerie. This transaction affirms Alco

Alcon to Acquire Aerie Pharmaceuticals, Inc., Enhancing its Ophthalmic Pharmaceutical Portfolio

Alcon's (ALC) robust innovation pipeline is delivering solid results as evidenced by the successful launch of new ATIOL roles and SiHy contact lenses.

Alcon (ALC) Q2 Earnings Surpass Estimates, Guidance Lowered

Alcon Inc. (NYSE:ALC ) Q2 2022 Results Conference Call August 10, 2022 8:00 AM ET Company Participants Dan Cravens - VP and Global Head IR David Endicott - CEO Tim Stonesifer - CFO Conference Call Participants Zach Weiner - Jeffries Chris Cooley - Stephens Daniel Buchta - ZKB Larry Biegelsen - Wells Fargo Matthew Mishan - KeyBanc Capital Ryan Zimmerman - BTIG Cecilia Furlong - Morgan Stanley Jeff Johnson - Baird Julien Dormois - BNP Paribas David Adlington - JPMorgan Operator Greetings and welcome to the Second Quarter 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode.

Alcon Inc. (ALC) CEO David Endicott on Q2 2022 Results - Earnings Call Transcript

GENEVA--(BUSINESS WIRE)--Alcon Reports Second Quarter 2022 Results

Alcon Reports Second Quarter 2022 Results

Does Alcon (ALC) have what it takes to be a top stock pick for momentum investors? Let's find out.

Here's Why Alcon (ALC) is a Great Momentum Stock to Buy

Despite bearing the brunt of inflationary pressure across both Total Surgical and Vision Care franchises, Alcon (ALC) succeeds in mitigating much of the impact through cost-improvement efforts.

News for Alcon Inc. - Registered Shares Stock (ALC)